Shots:

• The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos
• Cellenkos to receive $20M as licensing fee- ~$294.5M as development- regulatory and commercialization milestones along with royalties on sales of therapies- if approved. Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804 in benign and malignant hematology indications
• Following the exercising the global license option- Incyte to lead all activities and costs associated with research- development- and commercialization of the program

 ­ Ref: Businessiwre | Image: Businesswire